Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming

Open access
Mishra, Rajeev, Haldar, Subhash, Placencio, Veronica, Madhav, Anisha, Rohena-Rivera, Krizia, Agarwal, Priyanka, Duong, Frank, Angara, Bryan, Tripathi, Manisha, Liu, Zhenqiu, Gottlieb, Roberta A., Wagner, Shawn, Posadas, Edwin M., Bhowmick, Neil A.·2018·Journal of Clinical Investigation

Abstract

Prostate cancer is an androgen-dependent disease subject to interactions between the tumor epithelium and its microenvironment. Here, we found that epigenetic changes in prostatic cancer-associated fibroblasts (CAF) initiated a cascade of stromal-epithelial interactions. This facilitated lethal prostate cancer growth and development of resistance to androgen signaling deprivation therapy (ADT). We identified a Ras inhibitor, RASAL3, as epigenetically silenced in human prostatic CAF, leading to oncogenic Ras activity driving macropinocytosis-mediated glutamine synthesis. Interestingly, ADT further promoted RASAL3 epigenetic silencing and glutamine secretion by prostatic fibroblasts. In an orthotopic xenograft model, subsequent inhibition of macropinocytosis and glutamine transport resulted in antitumor effects. Stromal glutamine served as a source of energy through anaplerosis and as a mediator of neuroendocrine differentiation for prostate adenocarcinoma. Antagonizing the uptake of glutamine restored sensitivity to ADT in a castration-resistant xenograft model. In validating these findings, we found that prostate cancer patients on ADT with therapeutic resistance had elevated blood glutamine levels compared with those with therapeutically responsive disease (odds ratio = 7.451, P = 0.02). Identification of epigenetic regulation of Ras activity in prostatic CAF revealed RASAL3 as a sensor for metabolic and neuroendocrine reprogramming in prostate cancer patients failing ADT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci99397

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 159

Metadata

Authors
Mishra, R., Haldar, S., Placencio, V., Madhav, A., Rohena-Rivera, K., Agarwal, P., Duong, F., Angara, B., Tripathi, M., Liu, Z., Gottlieb, R. A., Wagner, S., Posadas, E. M., & Bhowmick, N. A.
Venue
Journal of Clinical Investigation
Published
2018-07-26
Volume
128
Issue
10
Pages
4472-4484
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2883663450
Cited by
159
References
10
FWCI
10.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. https://app.cochat.ai/papers/10.1172/jci99397
The paper
Mishra, R., Haldar, S., Placencio, V., Madhav, A., Rohena-Rivera, K., Agarwal, P., Duong, F., Angara, B., Tripathi, M., Liu, Z., Gottlieb, R. A., Wagner, S., Posadas, E. M., & Bhowmick, N. A. (2018). Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. Journal of Clinical Investigation. https://doi.org/10.1172/jci99397

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.